share_log

樂氏國際控股：截至2023年12月31日止年度 年度業績公告

YUES INTL HLDG: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 27 22:10
Summary by Futu AI
乐氏国际控股集团有限公司公布截至2023年12月31日止年度業績，收益約人民幣133.9百萬元，較上年度減少約25.4%。年度虧損約人民幣34.2百萬元，每股基本虧損約為人民幣3.28分。主要業務包括運輸、倉儲、廠內物流及定製服務，受到市場需求減少、運營成本增加等因素影響。公司於2023年10月收購中山海慧科企物流（集團）有限公司60%股權，以增強市場主導地位及營運效率。董事會不建議派付本年度末期股息。公司將繼續探索新業務機會，包括中醫藥相關業務，以實現可持續增長。
乐氏国际控股集团有限公司公布截至2023年12月31日止年度業績，收益約人民幣133.9百萬元，較上年度減少約25.4%。年度虧損約人民幣34.2百萬元，每股基本虧損約為人民幣3.28分。主要業務包括運輸、倉儲、廠內物流及定製服務，受到市場需求減少、運營成本增加等因素影響。公司於2023年10月收購中山海慧科企物流（集團）有限公司60%股權，以增強市場主導地位及營運效率。董事會不建議派付本年度末期股息。公司將繼續探索新業務機會，包括中醫藥相關業務，以實現可持續增長。
Lech International Holdings Group Limited announced its results for the year ended 31 December 2023 with revenues of approximately RMB133.9 million, down approximately 25.4% year-on-year. The annual loss was approximately RMB34.2 million and the basic loss per share was approximately RMB3.28 cents. Major businesses, including transportation, warehousing, in-plant logistics and custom services, are affected by reduced market demand and increased operating costs. In October 2023, the Company acquired a 60% stake in Zhongshan Hai HuiTech Logistics (Group) Co., Ltd., to enhance its market dominance and operational efficiency. The Board of Directors does not propose the payment of a dividend at the end of the year. The Company will continue to explore new business opportunities, including Chinese Pharma-related businesses, to achieve sustainable growth.
Lech International Holdings Group Limited announced its results for the year ended 31 December 2023 with revenues of approximately RMB133.9 million, down approximately 25.4% year-on-year. The annual loss was approximately RMB34.2 million and the basic loss per share was approximately RMB3.28 cents. Major businesses, including transportation, warehousing, in-plant logistics and custom services, are affected by reduced market demand and increased operating costs. In October 2023, the Company acquired a 60% stake in Zhongshan Hai HuiTech Logistics (Group) Co., Ltd., to enhance its market dominance and operational efficiency. The Board of Directors does not propose the payment of a dividend at the end of the year. The Company will continue to explore new business opportunities, including Chinese Pharma-related businesses, to achieve sustainable growth.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.